ArticleFrontiers in microbiology2021
Emergence of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in a Widespread ST11 Carbapenem-Resistant
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- From resistance mechanisms to therapy: Antimicrobial resistance in Gram-negative bacteria.Journal of microbiology (Seoul, Korea) · 2026Review
- Rapid Detection of Carbapenemase-Producing Enterobacterales Using a Luminescent Whole-Cell Biosensor.ACS infectious diseases · 2026Article
- Antimicrobial activity of gentamicin-conjugated monometallic and bimetallic nanoparticles against multidrug-resistant Klebsiella pneumoniae strains.Folia microbiologica · 2025Article
- Emerging resistance to novel β-lactam β-lactamase inhibitor combinations in Klebsiella pneumoniae bearing KPC variants.Journal of global antimicrobial resistance · 2025Article
- Impact of the double deletion ΔG242-T243 in KPC-2 in the effectiveness of ceftazidime-avibactam and imipenem-relebactam.Antimicrobial agents and chemotherapy · 2025Article
- Quantification of β-Lactamase Inhibition Using a Luminescent Whole-Cell Biosensor.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulentEmerging microbes & infections · 2024Article
- Genomic epidemiology and ceftazidime-avibactam high-level resistance mechanisms ofEmerging microbes & infections · 2024Article
- Characterization of a KPC-84 harboring Klebsiella pneumoniae ST11 clinical isolate with ceftazidime-avibactam resistance.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Identification of a Novel KPC Variant, KPC-204, Conferring Resistance to Both Carbapenems and Ceftazidime-Avibactam in an ST11Microorganisms · 2024Article
- Emergence of a clinicalFrontiers in cellular and infection microbiology · 2024Article
- Characteristic of KPC-12, a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in the Carbapenem-ResistantInfection and drug resistance · 2024Article
- Review
- Emergence of KPC-113 and KPC-114 variants in ceftazidime-avibactam-resistantMicrobiology spectrum · 2023Article
- Dynamic evolution of ceftazidime-avibactam resistance due to interchanges betweenFrontiers in cellular and infection microbiology · 2023Article
- Clinical Risk Factors and Microbiological and Intestinal Characteristics of Carbapenemase-ProducingMicrobiology spectrum · 2022Article
- Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.Infection · 2022Review
- Article
- Multiple Novel Ceftazidime-Avibactam-Resistant Variants ofMicrobiology spectrum · 2022Article
- The Genomic Characterization of KPC-ProducingInfection and drug resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.